Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
Lung cancer is treated with many conventional therapies, such as surgery, radiation, and chemotherapy. However, these therapies have multiple undesirable side effects. To bypass the side effects elicited by these conventional treatments, molecularly-targeted therapies are currently in use or under d...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/10/7/224 |
| _version_ | 1797708096761495552 |
|---|---|
| author | Zachary Schrank Gagan Chhabra Leo Lin Tsatsral Iderzorig Chike Osude Nabiha Khan Adijan Kuckovic Sanjana Singh Rachel J. Miller Neelu Puri |
| author_facet | Zachary Schrank Gagan Chhabra Leo Lin Tsatsral Iderzorig Chike Osude Nabiha Khan Adijan Kuckovic Sanjana Singh Rachel J. Miller Neelu Puri |
| author_sort | Zachary Schrank |
| collection | DOAJ |
| description | Lung cancer is treated with many conventional therapies, such as surgery, radiation, and chemotherapy. However, these therapies have multiple undesirable side effects. To bypass the side effects elicited by these conventional treatments, molecularly-targeted therapies are currently in use or under development. Current molecularly-targeted therapies effectively target specific biomarkers, which are commonly overexpressed in lung cancers and can cause increased tumorigenicity. Unfortunately, several molecularly-targeted therapies are associated with initial dramatic responses followed by acquired resistance due to spontaneous mutations or activation of signaling pathways. Acquired resistance to molecularly targeted therapies presents a major clinical challenge in the treatment of lung cancer. Therefore, to address this clinical challenge and to improve lung cancer patient prognosis, we need to understand the mechanism of acquired resistance to current therapies and develop additional novel therapies. This review concentrates on various lung cancer biomarkers, including EGFR, ALK, and BRAF, as well as their potential mechanisms of drug resistance. |
| first_indexed | 2024-03-12T06:17:20Z |
| format | Article |
| id | doaj.art-044ff804b28a4edb88fde80d1eece0b5 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T06:17:20Z |
| publishDate | 2018-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-044ff804b28a4edb88fde80d1eece0b52023-09-03T02:26:44ZengMDPI AGCancers2072-66942018-07-0110722410.3390/cancers10070224cancers10070224Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of ResistanceZachary Schrank0Gagan Chhabra1Leo Lin2Tsatsral Iderzorig3Chike Osude4Nabiha Khan5Adijan Kuckovic6Sanjana Singh7Rachel J. Miller8Neelu Puri9Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USADepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USADepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USADepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USADepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USADepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USADepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USADepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USADepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USADepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, IL 61107, USALung cancer is treated with many conventional therapies, such as surgery, radiation, and chemotherapy. However, these therapies have multiple undesirable side effects. To bypass the side effects elicited by these conventional treatments, molecularly-targeted therapies are currently in use or under development. Current molecularly-targeted therapies effectively target specific biomarkers, which are commonly overexpressed in lung cancers and can cause increased tumorigenicity. Unfortunately, several molecularly-targeted therapies are associated with initial dramatic responses followed by acquired resistance due to spontaneous mutations or activation of signaling pathways. Acquired resistance to molecularly targeted therapies presents a major clinical challenge in the treatment of lung cancer. Therefore, to address this clinical challenge and to improve lung cancer patient prognosis, we need to understand the mechanism of acquired resistance to current therapies and develop additional novel therapies. This review concentrates on various lung cancer biomarkers, including EGFR, ALK, and BRAF, as well as their potential mechanisms of drug resistance.http://www.mdpi.com/2072-6694/10/7/224lung cancermolecularly-targeted therapiesTKIresistanceinhibitor |
| spellingShingle | Zachary Schrank Gagan Chhabra Leo Lin Tsatsral Iderzorig Chike Osude Nabiha Khan Adijan Kuckovic Sanjana Singh Rachel J. Miller Neelu Puri Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance Cancers lung cancer molecularly-targeted therapies TKI resistance inhibitor |
| title | Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance |
| title_full | Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance |
| title_fullStr | Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance |
| title_full_unstemmed | Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance |
| title_short | Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance |
| title_sort | current molecular targeted therapies in nsclc and their mechanism of resistance |
| topic | lung cancer molecularly-targeted therapies TKI resistance inhibitor |
| url | http://www.mdpi.com/2072-6694/10/7/224 |
| work_keys_str_mv | AT zacharyschrank currentmoleculartargetedtherapiesinnsclcandtheirmechanismofresistance AT gaganchhabra currentmoleculartargetedtherapiesinnsclcandtheirmechanismofresistance AT leolin currentmoleculartargetedtherapiesinnsclcandtheirmechanismofresistance AT tsatsraliderzorig currentmoleculartargetedtherapiesinnsclcandtheirmechanismofresistance AT chikeosude currentmoleculartargetedtherapiesinnsclcandtheirmechanismofresistance AT nabihakhan currentmoleculartargetedtherapiesinnsclcandtheirmechanismofresistance AT adijankuckovic currentmoleculartargetedtherapiesinnsclcandtheirmechanismofresistance AT sanjanasingh currentmoleculartargetedtherapiesinnsclcandtheirmechanismofresistance AT racheljmiller currentmoleculartargetedtherapiesinnsclcandtheirmechanismofresistance AT neelupuri currentmoleculartargetedtherapiesinnsclcandtheirmechanismofresistance |